Literature DB >> 24533264

P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance.

Anne Lespine1, Cécile Ménez1, Catherine Bourguinat2, Roger K Prichard2.   

Abstract

Parasitic helminths cause significant disease in animals and humans. In the absence of alternative treatments, anthelmintics remain the principal agents for their control. Resistance extends to the most important class of anthelmintics, the macrocyclic lactone endectocides (MLs), such as ivermectin, and presents serious problems for the livestock industries and threatens to severely limit current parasite control strategies in humans. Understanding drug resistance is important for optimizing and monitoring control, and reducing further selection for resistance. Multidrug resistance (MDR) ABC transporters have been implicated in ML resistance and contribute to resistance to a number of other anthelmintics. MDR transporters, such as P-glycoproteins, are essential for many cellular processes that require the transport of substrates across cell membranes. Being overexpressed in response to chemotherapy in tumour cells and to ML-based treatment in nematodes, they lead to therapy failure by decreasing drug concentration at the target. Several anthelmintics are inhibitors of these efflux pumps and appropriate combinations can result in higher treatment efficacy against parasites and reversal of resistance. However, this needs to be balanced against possible increased toxicity to the host, or the components of the combination selecting on the same genes involved in the resistance. Increased efficacy could result from modifying anthelmintic pharmacokinetics in the host or by blocking parasite transporters involved in resistance. Combination of anthelmintics can be beneficial for delaying selection for resistance. However, it should be based on knowledge of resistance mechanisms and not simply on mode of action classes, and is best started before resistance has been selected to any member of the combination. Increasing knowledge of the MDR transporters involved in anthelmintic resistance in helminths will play an important role in allowing for the identification of markers to monitor the spread of resistance and to evaluate new tools and management practices aimed at delaying its spread.

Entities:  

Keywords:  Anthelmintic resistance; Macrocyclic lactones; Multidrug ABC transporters; P-glycoproteins

Year:  2011        PMID: 24533264      PMCID: PMC3862436          DOI: 10.1016/j.ijpddr.2011.10.001

Source DB:  PubMed          Journal:  Int J Parasitol Drugs Drug Resist        ISSN: 2211-3207            Impact factor:   4.077


  185 in total

1.  Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.

Authors:  Catherine Bourguinat; Joseph Kamgno; Michel Boussinesq; Charles D Mackenzie; Roger K Prichard; Timothy G Geary
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

2.  Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells.

Authors:  Jacques Dupuy; Michel Alvinerie; Cecile Ménez; Anne Lespine
Journal:  Chem Biol Interact       Date:  2010-06-01       Impact factor: 5.192

3.  Praziquantel resistance.

Authors:  Sanaa S Botros; James L Bennett
Journal:  Expert Opin Drug Discov       Date:  2007-10       Impact factor: 6.098

4.  Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility.

Authors:  Shanta M Messerli; Ravi S Kasinathan; William Morgan; Stefani Spranger; Robert M Greenberg
Journal:  Mol Biochem Parasitol       Date:  2009-05-03       Impact factor: 1.759

5.  Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus.

Authors:  W J Blackhall; H Y Liu; M Xu; R K Prichard; R N Beech
Journal:  Mol Biochem Parasitol       Date:  1998-09-15       Impact factor: 1.759

6.  MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin.

Authors:  Alain Roulet; Olivier Puel; Stéphane Gesta; Jean-François Lepage; Marlene Drag; Mark Soll; Michel Alvinerie; Thierry Pineau
Journal:  Eur J Pharmacol       Date:  2003-01-24       Impact factor: 4.432

7.  In vitro and in vivo interaction of moxidectin with BCRP/ABCG2.

Authors:  Miriam Perez; Alba G Blazquez; Rebeca Real; Gracia Mendoza; Julio G Prieto; Gracia Merino; Ana I Alvarez
Journal:  Chem Biol Interact       Date:  2009-02-23       Impact factor: 5.192

Review 8.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

9.  P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation.

Authors:  Ernesto Yague; Angel L Armesilla; Georgina Harrison; James Elliott; Alessandro Sardini; Christopher F Higgins; Selina Raguz
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

10.  Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.

Authors:  A Pál; D Méhn; E Molnár; S Gedey; P Mészáros; T Nagy; H Glavinas; T Janáky; O von Richter; G Báthori; L Szente; P Krajcsi
Journal:  J Pharmacol Exp Ther       Date:  2007-03-08       Impact factor: 4.030

View more
  57 in total

1.  shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.

Authors:  Ping Xu; Yong-Fang Jiang; Jing-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Tissue expression pattern of ABCG transporter indicates functional roles in reproduction of Toxocara canis.

Authors:  Yong-Li Luo; Guang-Xu Ma; Yong-Fang Luo; Ce-Yan Kuang; Ai-Yun Jiang; Guo-Qing Li; Rong-Qiong Zhou
Journal:  Parasitol Res       Date:  2018-02-08       Impact factor: 2.289

3.  In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis.

Authors:  Noemi Cowan; Mireille Vargas; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Gene expression analysis of ABC transporters in a resistant Cooperia oncophora isolate following in vivo and in vitro exposure to macrocyclic lactones.

Authors:  J De Graef; J Demeler; P Skuce; M Mitreva; G Von Samson-Himmelstjerna; J Vercruysse; E Claerebout; P Geldhof
Journal:  Parasitology       Date:  2013-01-02       Impact factor: 3.234

5.  Efficiency of Target Larvicides Is Conditioned by ABC-Mediated Transport in the Zoonotic Nematode Anisakis pegreffii.

Authors:  Ivona Mladineo; Željka Trumbić; Jerko Hrabar; Anamarija Vrbatović; Ivana Bušelić; Ivana Ujević; Romana Roje-Busatto; Ivana Babić; Concetta Messina
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

6.  A sensitive and selective LC-MS/MS method for quantitation of ivermectin in human, mouse and monkey plasma: clinical validation.

Authors:  Yashpal S Chhonker; Liping Ma; Constant Edi; Daryl J Murry
Journal:  Bioanalysis       Date:  2018-10-16       Impact factor: 2.681

7.  Ion channels and drug transporters as targets for anthelmintics.

Authors:  Robert M Greenberg
Journal:  Curr Clin Microbiol Rep       Date:  2014-12

Review 8.  ABC multidrug transporters in schistosomes and other parasitic flatworms.

Authors:  Robert M Greenberg
Journal:  Parasitol Int       Date:  2013-03-06       Impact factor: 2.230

Review 9.  New approaches for understanding mechanisms of drug resistance in schistosomes.

Authors:  Robert M Greenberg
Journal:  Parasitology       Date:  2013-04-03       Impact factor: 3.234

Review 10.  Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.

Authors:  P S Thakur; A M Khan; S Talegaonkar; F J Ahmad; Z Iqbal
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.